US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by TRACON Pharmaceuticals, Inc.

News headline image
TRACON Pharmaceuticals Announces it Will Wind Down Operations
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Reverse Stock Split
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON
News headline image
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
From TRACON Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TCON